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Tissue microarray (TMA) technology is a relattively recent development that is mainly used to sample a large set of tumors stored as archit
val material in order to assess the expression of multiple 
specific biomarkers. The technique was first described in 
1998 by Kononen et al.1 Through this technique, it was 
possible to avoid the tedious and more expensive prot
cess of examining a large number of tumor tissues with 
the conventional wholetsection method. The TMA 
method greatly facilitates comprehensive molecular 
and protein expression profiling of cancer specimens 
stored as archival formalintfixed and paraffin embedded 
(FFPE) blocks with a minimal tissue requirement. By 
using TMA, it is possible to array up to 1000 tumors on 
a onet glass slide, which then can be analyzed for mult
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BACkgROuND: analysis of immunohistochemical expression of a large number of tumor tissue samples with 
conventional techniques is costly, tedious and slow. tissue microarray (tma) technology can facilitate the sam-
pling of over 500 tumors on a one-glass slide, which then can be analyzed by fluorescence in situ hybridiza-
tion (fish), rna in situ hybridization, or immunohistochemistry. We attempted to validate this technique in 
breast cancer specimens by comparing the staining result obtained by tma with the conventional whole-section 
method.
PATIENTS AND METHODS: eighty cases of breast cancer of diverse subtypes were used to build a breast cancer 
biomarker evaluation model. serial sections of the recipient block were immunostained with a panel of 4 anti-
bodies (er, pr, her2 and p53). concordance of immunohistochemical expression between tma sections and 
whole-sections was expressed as a k statistic. 
RESulTS: target tumors were accurately sampled by two cores in 19 of 26 donor blocks, and by only one core 
in 5 blocks. failure to sample tumor was seen in 2 blocks. concordance between the staining results of tma and 
whole sections was good for pr (k=0.67) and er (k=0.67) and very good for p53 (k=0.91) and her2 (k=0.91), 
when all the 26 recipient blocks were included. the rate improved to excellent for p53 (k=1.0) and did not 
change for the other markers when concordance analysis was limited to recipient blocks that had been sampled 
by two cores.
CONCluSION: tma is a reliable technique for examining a large set of tumors. it shows immunostaining 
scores comparable to those obtained by conventional whole-section evaluation in breast cancer. however, 
some alterations are not detected due to heterogeneity of biomarker expression inherent in these tumors, but 
this shortfall can be improved.
tiple biomarkers of different types. These include genes 
(by florescence in situ hybridization (ISH) and RNA 
ISH) and proteins (by immunohistochemistry).1,2 
Lately, TMA technology has been extensively used for 
the evaluation of the prognostic and diagnostic utilt
ity of multiple immunohistochemical markers in large 
tumor set studies.3 Due to the small size of individut
ally arrayed tissue samples (diameter of 0.6 mm), it is 
possible to postulate that these small cores may not be 
representative of their donor tumors. Indeed, it is unt
avoidable that at least some alterations present in the 
original tumor block may not be detected if the analysis 
is restricted to cores measuring 0.6 mm.4t6
Breast carcinomas display intratumoral heterogenet
ity, and it is not uncommon to see a varied expression of 
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protein biomarkers such as hormonal markers (estrogen 
and progesterone receptors) as well as HER2 and p53 
within the same tumor.4,7 Given the issue of potential 
lack of a representative of the original tumor due to the 
small size of the core, it is important to take into considt
eration the number of small “random” core biopsies that 
have to be taken into account for tumor heterogeneity.
The aim of this study was to validate the utility of 
TMA technology when used in a population of breast 
carcinomas encountered in Saudi Arabia by comparing 
the staining result obtained through a TMA analysis with 
the result of the conventional wholetsection method.
PATIENTS AND METHODS
The breast cancer study module constructed earlier 
(manuscript in preparation) was used to validate the 
TMA analysis. The study material in this module cont
sisted of slides and tissue blocks from 80 breast cancer 
specimens retrieved from the archives of the Department 
of Pathology and Laboratory Medicine, King Fahad 
National Guard Hospital, Riyadh, Saudi Arabia. These 
specimens were accessed between 1996 and 2002. The 
patients were treated at this hospital either by lumpect
tomy or modified radical mastectomy and the majority 
of these patients were Saudi. None of the included cases 
received preoperative radiotherapy or chemotherapy. All 
breast cancer included invasive carcinomas; 65 were int
vasive ductal carcinomas and the rest were of the lobular 
type. Hematoxylin and eosin (H&E) stained slides and 
paraffin blocks were available for all cases. For each case, 
the slides were reviewed, the diagnosis confirmed, and 
the tumor type assessed.
Tissue microarray construction
While reviewing the H&E stained slides, a slide with a 
representative tumor was selected from each case, and 
an area of tumor on the selected H&E slide was circled. 
The corresponding paraffin block was retrieved and the 
marked slide was aligned with the surface of the corret
sponding donor block to guide marking the selected area 
on the paraffin block with a feltttipped marker. Using a 
tissue microarrayer (Beecher Instruments, Silver Spring, 
MD), the area of interest from the donor block was cored 
twice with a 0.6 mmtdiameter cylinder and transferred 
to a recipient paraffin block. Serial sections of the recipit
ent block were stained with H&E with four antibodies 
(to ER, PR, HER2 and p53) to assess adequacy. For the 
validation study, a novel method was used, whereby 26 
of the cored donor blocks were serially sectioned and 
stained with H&E and immunostained with the same 
four antibodies. H&E of the recipient block sections 
were examined to determine the accuracy of sampling 
the target tumor. These blocks were selected based on 
the availability of a large area of tumor for proper evalut
ation of adjacent tumor to the cored spots.
Immunohistochemistry
The avidintbiotin (ABC) method was used for immut
nostaining and applied to formalintfixed and paraffint
embedded tissue. Serial sections of the recipient paraffin 
block and the selected cored donor block were cut at 3 
µm, deparaffinized with xylene and rehydrated through a 
series of graded alcohols. Sections were stained with the 
panel of 4 antibodies. An automated stainer (Ventana, 
Tucson, AZ) was used according to the manufacturer’s 
guidelines for ER (clone 1D5), PR (clone pgr6), HER2 
(Dako, polyclonal) and p53 (clone DO7) antibodies.
Immunohistochemical scoring
TMA sections and wholetsections stained with the 
various antibodies were then scored and expressed as a 
dichotomous variable (positive, negative) or uninterpret
table. ER and PR were evaluated according to nuclear 
staining and staining of 1% or more of the tumor cell 
nuclei were considered to be a positive result. P53 staint
ing was considered as immunopositive when >10% of 
tumor cell nuclei stained. HER2 was expressed as posit
tive when more than 30% of tumor cells showed strong 
and circumferential membranous staining (correspondt
ing to 3+ staining in routine clinical practice). The same 
scoring method was used for TMA and wholetsections. 
Scores were entered into a Microsoft Excel spreadsheet. 
Technically unsatisfactory results were eliminated from 
further consideration. Score results for duplicate cores 
were consolidated into one score, where a score for posit
tive immunostaining would always supersede a negative 
or uninterpretable result. 
Statistical analysis
Both the complete agreements (also denoted as cont
cordance) and the kappa statistic (which is a measure 
of agreement correcting for agreement by chance) were 
calculated to measure agreement between the scores on 
the TMA and scores on wholetsection slides. Agreement 
was considered poor if k<0.2, slight if 0.21<k<0.4, 
fair if 0.41 <k<0.6, good if 0.61<k<0.8, very good if 
0.81 <k<0.92 and excellent if 0.93<k≤1.0.7 Analysis 
was performed by using SPSS software version 12.0 
(Chicago, USA).
RESulTS
Target tumors were accurately sampled by either one or 
two cores in 24 of 26 donor blocks (92.3%), with a failt
ure rate of 7.7%. Nineteen donor blocks were accurately 
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sampled by two cores (73.1%) and five by only one core 
(19.2%) (Figure 1). The target tumor was missed in two 
blocks.
Table 1 illustrates the scoring result, concordance 
rate and kappa statistics. Fifteen of 24 accurately cored 
tumors showed positive staining for ER in wholetsect
tions, and 11 of these 15 were scored positive by the 
TMA technique (Figure 2A, B). None of the tumors 
that were negative on the wholetsection were scored as 
positive on the TMA cores. The same result was obt
tained for PR. The concordance rate was 83.3% and 
k=0.673 (good agreement) for either marker. One case 
was missed and scored as negative for HER2 in TMA 
compared to the wholetsection, and similarly none of 
those cases scored as negative in the wholetsection 
was called positive by TMA (Figure 2C, D). This gave 
a concordance rate of 95.8% and k=0.91 (very good 
agreement). The p53 staining was uninterpretable in 
one tumor, which reduced the total number of tumors 
available to calculate the concordance to 23. However, 
similar to HER2, only one tumor was missed in the 
TMA analysis and was scored as negative. None of the 
negative tumors by wholetsection were scored as posit
tive on the TMAs. The concordance rate for p53 was 
95.6% and k=0.91 (very good agreement). The five 
tumors that were accurately cored by only one core 
showed at least one undercalled tumor by TMA, when 
compared to the whole section, except for HER2 staint
ing that showed a 100% concordance rate.
DISCuSSION
TMA technology has begun to impact significantly on 
our ability to evaluate and understand the molecular 
basis of disease pathogenesis. After its introduction in 
1998, it has been applied to the immunohistochemical 
analysis of biomarker expression in various malignant
cies, including breast carcinomas, as a means of ident
tifying prognostic or diagnostic signatures for clinical 
use.1t3,9,10 Although TMA analysis has the potential to 
facilitate high throughput analysis of hundreds of tissues 
simultaneously, there may be inherent limitations, since 
the evaluation of biomarker expression is reduced from 
wholetsection analysis to tissue cores of only 0.6 mm in 
diameter. This potential limitation could impact signifit
cantly on the analysis of tumors exhibiting intratumoral 
heterogeneity.2,4 This study was carried out to validate 
this technique in breast carcinomas encountered in the 
Saudi population and evaluate the correlation between 
biomarker expression in TMA and whole sections. The 
technique used in this study to validate the TMA allows 
the observer to examine the areas adjacent to where the 
cores were arrayed and provides insight and explanation 
to the discordant results.
The study has shown that the expression pattern of 
the four antibodies tested can be assessed through TMA 
of breast cancer with good reliability (k=0.67) for ER 
and PR and very good reliability (k=0.91) for HER2 
and p53 in comparison with whole sections. There were 
a b
Figure 1. Hematoxylin and eosin stained sections of the cored donor block (a) and corresponding core (b). 
Table 1. Concordance rate and k statistics between TMa and whole-section scoring.
ER PR HER2 p53
   Positive score in  
   whole-section 15/24 15/24 9/24 9/23
   Positive score in 
   TMa 11/24 11/24 8/24 8/23
   Positive TMa 
   scores vs. positive   
   whole-section
11/15 11/15 8/9 8/9
   Concordance rate 83.3% 83.3% 95.8% 95.6%
   k 0.673 0.673 0.909 0.907
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more discordant cases with respect to ER and PR staint
ing than to HER2 and p53 (4 versus 1). The discordant 
cases in ER and PR showed either a weaker or lower 
percentage of positive nuclei in the whole section, with 
none of these showing positive nuclei in more than 50% 
of the tumor. In contrast, few of the concordant cases 
showed a lower percentage of positive nuclei. However, 
some of these positive nuclei were present in the examt
ined cores. The cuttoff rate of 1% of cells scoring posit
tive was used for scoring the ER and PR results and was 
based on the most recent recommendation of reporting 
hormonal markers in breast cancer.11
The single discordant case for HER2 showed strong 
membranous staining in the whole section. However, 
this staining was not equally distributed. The nuclear 
staining of p53 expression was strong and diffused in 
the discordant case in the whole section slide of this 
tumor.
These findings prove that the concordance between 
immunohistochemistrytbased expression of the 4 ant
tibodies on TMA and the wholetsection slide is det
pendent on the scoring system used, and the antibody 
tested.4t6,10 It is also possible that there are other fact
tors such as an altered protein expression pattern due to 
technical staining factors, e.g. fluidic distribution may 
influence one degree of discordance between these two 
methods. Background staining is usually more distinct 
on whole section slides than in small cores might have 
contributed to this.12 When the cuttoff for scoring ER 
and PR was raised to 50%, the number of discordant 
cases dropped from four to two cases. However, this was 
not enough to eliminate this discordance. It is possible 
to postulate that this latter observation indicates that 
it is not only the scoring system used that can explain 
the discordance incidence for TMA analysis. The dist
cordance rate in HER2 and p53 staining was much 
less, since a higher cuttoff scoring system was used. 
Technical factors such as fluidics may explain the dist
cordant case of p53 staining.
Several studies4t7,9,10,13t15 have been conducted to valit
date TMA analysis in malignancies from various organs 
and showed agreement ranging from good to excellent. 
Breast cancer TMA validation studies4,7 showed that 
TMA was a valuable and accurate method for analyt
Figure 2. immunostained sections of the cored block and corresponding core, er (a,b) and Her2 (c,d). 
a b
c d
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sis of protein expression in large archival cohorts and 
provided highly comparable results in the assessment 
of HER2 protein levels. Furthermore, a study has valit
dated TMA use for even a heterogeneous biomarker 
like Kit67 in breast carcinoma. Ruiz et al has shown the 
efficacy of TMA in heterogeneous biomarkers (Kit67) 
in a study of 2,517 breast tissues.16 
Although the intention of this study was not to evalut
ate the proper number of cores that should be obtained 
to improve the degree of agreement of TMA in comparit
son to whole section, it was observed that the agreement 
level improved slightly with two cores versus one. This 
did not reach statistical significance possibly due to the 
small number of cases conducted. Many studies have 
shown that more cores would improve the agreement 
level and reduce the limitation of tumor heterogenet
ity.2,5,6,9,17 In most TMA modules, it is recommended 
to obtain at least two cores per tumor to improve its 
reliability.1,2 The population evaluated has not, to our 
knowledge, been studied with respect to heterogeneity 
of breast cancer biomarker expression and showed a 
similar concordance between whole section and TMA 
to the population analyzed previously.
TMA is a reliable tool to investigate protein exprest
sion patterns in breast cancer. The agreement between 
scores on wholetsection slides and TMA varies with 
the antigens tested and the scoring systems used. The 
best results are found with antigens which are diffusely 
expressed in a tumor. Concordance between TMA and 
wholetsections are likely to be lower in the presence of 
focal expression of the biomarker and a low number of 
positive cells. Examining selected sections from donor 
blocks following coring can be used reliably to ensure 
that the conducted TMA is a representation of the 
original tumors and can help to evaluate the status of 
difficult or uninterpretable cores.
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